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Angiogenesis is a characteristic feature of tumours and other disorders. The human monoclonal antibody L19- SIP targets the extra
domain B of fibronectin, a marker of angiogenesis expressed in a range of tumours. The aim of this study was to investigate whole
body distribution, tumour localisation and the potential of radioimmunotherapy with the L19-small immunoprotein (SIP) in colorectal
tumours. Two colorectal tumour models with highly different morphologies, the SW1222 and LS174T xenografts, were used in this
study. Localisation and retention of the L19-SIP antibody at tumour vessels was demonstrated using immunohistochemistry and Cy3-
labelled L19-SIP. Whole body biodistribution studies in both tumour models were carried out with
125I-labelled L19-SIP. Finally,
131I-labelled antibody was used to investigate the potential of radioimmunotherapy in SW1222 tumours. Using immunohistochem-
istry, we confirmed extra domain B expression in the tumour vasculature. Immunofluorescence demonstrated localisation and
retention of injected Cy3-labelled L19-SIP at the abluminal side of tumour vessels. Biodistribution studies using a
125I-labelled antibody
showed selective tumour uptake in both models. Higher recorded values for localisation were found in the SW1222 tumours than in
the LS174T (7.9 vs 6.6%IDg
 1), with comparable blood clearance for both models. Based on these results, a radioimmunotherapy
study was performed in the SW1222 xenograft using
131I-Labelled L19-SIP (55.5MBq), which showed selective tumour uptake,
tumour growth inhibition and improved survival. Radio- and fluorescence-labelled L19-SIP showed selective localisation and retention
at vessels of two colorectal xenografts. Furthermore,
131I-L19-SIP shows potential as a novel treatment of colorectal tumours, and
provides the foundation to investigate combined therapies in the same tumour models.
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Radioimmunotherapy (RIT), the targeting of radiation to the
tumour using monoclonal antibodies against tumour-associated
antigens, has been used as a form of cancer treatment in both
animal xenograft models as well as in humans (Pedley et al, 2001;
Koppe et al, 2005). This form of therapy has the advantage of
selectively targeting the tumour while reducing systemic toxicity.
Solid tumours possess a heterogeneous pathophysiology and,
therefore, the effectiveness of RIT depends on a range of factors
including distribution of antibody uptake within the whole tumour
mass and tumour vascularity.
Angiogenesis, the development of new blood vessels from pre-
existing vessels, is a common feature of solid tumours and other
diseases such as blinding ocular disorders and rheumatoid
arthritis. Angiogenic processes are regulated by a number of
cell surface receptors and extracellular adhesion molecules
(Ebbinghaus et al, 2004). The ability to selectively target
angiogenic molecules (markers) is useful for the delivery of
therapeutic agents to the tumour. One potential marker for
neovasculature is the extra domain B (ED-B) of fibronectin (FN).
Fibronectins are high-molecular-weight-adhesive glycoproteins
abundantly expressed in vivo in the extracellular matrix and in
body fluid (Kaspar et al, 2006). These play an important role in a
number of biological phenomena such as maintenance of normal
cell morphology, cell migration, haemostasis and thrombosis,
wound healing, and oncogenic transformation (Castellani et al,
1994). Alternative splicing in the primary transcript results in
multiple FN transcripts of the single copy gene. Three FN isoforms
are expressed in tumour tissue and transformed cells, these include
IIICS, extra domain A and ED-B (Ebbinghaus et al, 2004; Kaspar
et al, 2006).
Extra domain-B domain is a complete type III repeat composed
of a sequence of 91 amino acids, coded by a single exon and is the
most conserved region of FN. It displays 100% homology in all
mammalian species (Zardi et al, 1987). It is usually absent in both
plasma and tissue FN of adults, except in regenerating tissues, such
as some vessels in the endometrium. However, it is overexpressed
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sduring active tissue remodelling, for example, angiogenesis in
tumours, wound healing and embryogenesis (Ebbinghaus et al,
2004; Kaspar et al, 2006). It has been shown to accumulate
specifically around neovasculature in studies of many different
tumour types, making it a good marker for angiogenesis
(Carnemolla et al, 1989; Kaczmarek et al, 1994; Neri et al, 1997;
Kosmehl et al, 1999; Tarli et al, 1999; Viti et al, 1999; Demartis
et al, 2001; Castellani et al, 2002; Birchler et al, 2003; Ebbinghaus
et al, 2004).
Human antibodies against the ED-B domain of FN, termed ‘L19’,
have been isolated using different technologies (Pini et al, 1998;
Borsi et al, 2002; Alessi et al, 2004). These include a complete
human IgG, dimeric scFv ((scFv)2) and a small immunoprotein
(SIP). The L19-SIP is an 80kDa fragment composed of two scFv
fused to the human As2–CH4 domain to provide a covalent
stabilisation of the dimer (Li et al, 1997; Borsi et al, 2002).
Several fusion proteins based on the L19 antibody have been
produced and characterised (Birchler et al, 1999; Nilsson et al,
2001; Halin et al, 2002; Halin et al, 2003; Ebbinghaus et al, 2005;
Fabbrini et al, 2006). Furthermore, several radiolabelled deriva-
tives of the L19 antibody have been studied in biodistribution
experiments (Borsi et al, 2002) as well as being evaluated in clinical
radioimmunscintigraphy studies (Santimaria et al, 2003). Biodis-
tribution experiments and RIT studies with the L19-SIP antibody
have been carried out in tumour-bearing mice and rats, and have
demonstrated selective localisation in different tumour models, for
example, human melanomas, mouse embryonal teratocarcinomas,
human head and neck squamous cell carcinomas, and rat gliomas
(Borsi et al, 2002; Berndorff et al, 2005; Spaeth et al, 2006; Tijink
et al, 2006). Finally, the therapeutic potential of
131I-L19-SIP is
currently being investigated in clinical trials in Italy and Switzer-
land (Kaspar et al, 2006).
In the present study, we have investigated for the first time, the
distribution of the L19-SIP antibody in two human colorectal
tumour models (SW1222 and LS174T), using both radio- and
fluorescence-labelled antibody. We demonstrate that the radio-
labelled antibody localises selectively in both tumour models.
Furthermore, by employing high-resolution multi-fluorescence
microscopy, we have been able to show that the antibody
localisation is specific to the abluminal surface of the vessel.
Finally, we show that RIT with
131I-L19-SIP causes tumour growth
retardation and prolongs survival in preliminary therapy studies.
MATERIALS AND METHODS
Antibody
The L19-SIP (Mw 80kDa), which targets the ED-B domain of FN
consists of a fusion between two scFv and a CH4 domain of the
human IgE, which mediates the homodimerisation of recombinant
antibody (Borsi et al, 2002).
Xenografts
The human colorectal adenocarcinoma cell lines SW1222 and
LS174T were used to develop subcutaneous xenograft models in
the flanks of female nude mice (Pedley et al, 2001). SW1222
tumours are well differentiated and highly vascularised in
comparison to the less differentiated and more poorly vascularised
LS174T tumours (Pedley et al, 2002), and both represent
morphologies frequently observed in the clinic.
Passaging was by subcutaneous implantation of small tumour
pieces (B1mm
3). Biodistribution experiments were carried out
when tumours reached approximately 1cm
3. For therapy experi-
ments, mice with palpable tumours of approximately 0.1cm
3 were
used. All animal experiments were in compliance with the UK Co-
ordinating Committee on Cancer Research (UKCCCR) guidelines
for the Welfare of Animals in Experimental Neoplasia.
For immunohistochemistry and immunofluorescence staining,
tumours were isolated, snap frozen in liquid nitrogen and stored at
 80C.
ED-B antigen expression
Immunohistochemistry was performed on 10mm thick cryostat
sections of both SW1222 and LS174T tumours after fixing in
acetone for 10min at room temperature. Following blocking of
endogenous peroxidase with 0.3% of H2O2/methanol for 15min at
room temperature, sections were first incubated in 3% normal goat
serum/phosphase-buffered saline (PBS) for 30min, followed by
a1h incubation with 2mgml
 1 L19-SIP antibody at room
temperature. After washing with PBS, the sections were then
incubated with a horseradish peroxidase conjugated goat anti-
human antibody (DAKO UK Ltd, Ely, UK) for 1h at room
temperature, rinsed in PBS, and then incubated with the avidin–
biotin complex (Vector Laboratories Ltd, Orton Southgate, UK)
following the manufacturer’s instructions. Sections were developed
with 3,3-diaminobenzidine (Sigma-Aldrich Company Ltd, Gillingham,
UK) and counterstained with haematoxylin. Finally, sections were
mounted in dibutyl phthalate xylene and visualised under a light
microscope.
Fluorescence-labelled antibody studies
Fluorescence labelling The L19-SIP antibody was labelled with
Cy3-NHS (Amersham Pharmacia, Little Chalfont, UK) according
to the manufacturer’s instructions. The final antibody to dye ratio
was 1:5. A total of 100mg of labelled antibody was injected
intravenously into the tail of the mouse 6h before killing. Tumours
were then excised, snap frozen in isopentane (cooled in liquid
nitrogen), and stored at  801C until sectioned.
Tumour parameters To relate Cy3-L19-SIP antibody distribution
to tumour morphology/pathophysiology, the following parameters
were studied by multi-fluorescence microscopy:
(1) Perfusion: the in vivo DNA-binding dye Hoechst 33342
(10mgkg
 1) was injected intravenously 1min before the mice
were killed.
(2) Blood vessels: an anti-CD31 antibody was used to stain for
blood vessel distribution, and the relevant immunohisto-
chemical staining procedures were performed (see below).
(3) Nuclear staining: DAPI (4,6 diamidino-2-phenylindole) was
used as a nuclear marker. This produces a blue fluorescence
when bound to DNA.
Multi-fluorescence microscopy Sections (10mm) were first fixed
in acetone for 10min at room temperature, and then incubated
with a 1:2 dilution of unconjugated anti-CD31 rat anti-mouse
antibody (a kind gift from Professor A Mantovani) for 1h at room
temperature. After rinsing in PBS, sections were incubated with a
1:200 dilution of an Alexa Fluor 488 goat anti-rat antibody
(Invitrogen Ltd, Paisley, UK) for 1h at room temperature. After
further rinsing with PBS, sections were mounted in either
mounting medium containing DAPI (Vector Laboratories) or in
PBS and viewed using an Axioskop 2 microscope (Carl Zeiss Ltd,
Welwyn Garden City, UK), fitted with a computer-controlled
motorised stage. Images were captured by an AxioCam digital
colour camera using KS300 image analysis software (Zeiss, UK)
(Pedley et al, 2002; El-Emir et al, 2005). Briefly, injected Hoechst
33342 and DAPI staining were visualised under a UV filter.
Injected Cy3-L19-SIP and the CD31 signal were visualised under
rhodamine and FITC filters, respectively. Both composite tiled
images, consisting of a large number of individual fields, as well as
high-resolution single images, for three different fluorophores
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s(stained for three different parameters), were generated. Finally,
the fluorescence images were then co-registered using Adobe
Photoshop software, resulting in a new multi-channel image
showing the inter-relationship between the overlapping fluores-
cently labelled structures.
Radiolabelled antibody studies
125I-labelling L19-SIP was labelled according to the IODO-GEN
method as described by Visser et al (2001). Briefly, to an IODO-
GEN-coated glass tube, the following was added: 50ml 0.5 M
phosphate buffer, pH 7.4; 250mg L19-SIP (0.5mgml
 1) in 0.1 M
phosphate buffer, pH 6.8; 50.18MBq
125I (Amersham Biosciences).
The reaction was stopped after 4min by the addition of 100mlo f
ascorbic acid (25mgml
 1, pH 5). The solutions from two separate
labellings were combined and purified on a PD-10 column and
eluted with 0.9% NaCl/ascorbic acid (5mgml
 1, pH 5.0). For the
PD-10 column, the first 2.5ml (1ml sample volume and the first
1.5ml) were discarded and the radiolabelled L19-SIP was collected
in the next 2ml.
131I-labelling Preparation of
131I-L19-SIP for therapy was per-
formed according to the ‘IODO-GEN-coated MAb method’ (Visser
et al, 2001; Tijink et al, 2006). Briefly,
131I (444MBq) was added to
a glass vial in 1ml NaOH (1mmoll
 1), after which 10ml of ascorbic
acid (1.4mgml
 1) was added. After 5min, 400ml of phosphate
buffer (0.5 M, pH 7.2) was added, followed by 3ml L19-SIP
(approximately 1.5mg) and 35ml IODO-GEN solution (1mgml
 1).
After 3min, the reaction was stopped by adding 100ml ascorbic
acid (25mgml
 1) followed after 5min by the addition of 50ml
human serum albumin (20%). The solution was then purified on a
PD-10 column and eluted with 0.9% NaCl/ascorbic acid
(5mgml
 1, pH 5.0). The initial 2.7ml eluate (2.2ml sample
volume and the first 0.5ml) was discarded and the radiolabelled
L19-SIP was collected in the next 3.0ml.
Analyses Thin layer chromatography (TLC) was used to assess
radiopharmaceutical purity (silica gel Si60 stationary phase and
citrate buffer (20mM, pH 5.0) mobile phase).
The immunoreactivity of the radiolabelled protein was assessed
on a 200ml volume ED-B sepharose column saturated with 0.25%
BSA in PBS. An aliquot of radiolabelled antibody was applied to
the column, which was then rinsed with 1.5ml of 0.25% BSA in
PBS to remove non-specifically bound antibodies. Bound material
was eluted using 1.5ml of 0.1 M TEA, pH 11. The radioactivity of
the bound and unbound material was counted, using a g-counter,
and the immunoreactive percentage was calculated.
Biodistribution of
125I-L19-SIP Biodistribution experiments with
the
125I-L19-SIP were carried out in both SW1222 and LS174T
xenograft-bearing mice. Mice were injected in the tail vein with
8mg (0.26MBq) of radiolabelled antibody and dissected at 1, 3, 6 or
24h after injection. For each time point, four mice were killed and
the following organs were excised, weighed and counted in a
g-counter (Cobra Multi Gamma Model 5010-Packard, UK): blood,
tumour, liver, spleen, kidney, intestine, heart, lung, brain, muscle,
stomach and tail. The radioactive content of the different organs
was expressed as the percentage of injected dose per gram of tissue
(%IDg
 1). Biodistribution experiments were analysed using
Microsoft office Excel 2003.
Therapy Therapy experiments with
131I-L19-SIP were performed
on SW1222 xenograft-bearing mice. To confirm that the
131I-
labelled L19-SIP was selectively localizing to the tumour, and to
compare localisation with
125I-labelled L19-SIP, a biodistribution
study was first performed with the former. Each mouse was
injected in the tail vein with 1.6mg (0.75MBq) of radiolabelled
antibody, and groups of four mice killed at 3, 24 and 72h after
injection. Later time points (i.e., 24 and 72h) were included to
investigate prolonged antibody retention, which is important for
RIT efficacy. The following organs were excised, weighed and
counted in a g-counter: blood, tumour, liver, spleen, kidney, lung,
colon, muscle, brain and stomach. The radioactive content of the
different organs was expressed as %IDg
 1.
For the RIT experiments, a group of four mice was injected,
intraperitonially, with 117.5mg (55.5MBq)
131I-L19-SIP per mouse.
A second group of six mice were used as untreated controls.
During treatment, tumours were measured twice weekly for a
period of approximately 140 days, and tumour volume was
estimated as the measurement of length width height/2 (Pedley
et al, 2001). As well as observing general condition (e.g.,
respiratory distress, abnormal behaviour and no food/fluid
intake), toxicity was assessed by using body weight measured
every 3–4 days, as a surrogate marker. Mice were killed when
tumours reached approximately 1.5cm
3 in volume. Therapy
experiments were analysed using Microsoft office Excel 2003 and
SPSS software. Survival was calculated using Kaplan–Meier
analysis and showed significant correlation using the log-rank
test (P¼0.0034). Suppression of tumour growth was analysed
using a non-parametric test (Mann–Whitney U-test). This showed
a significant difference in tumour size between untreated and
therapy groups at day 13 (P¼0.038), which was sustained up until
day 25 (P¼0.011).
RESULTS
Antigen expression
Before distribution studies with fluorescence-labelled L19-SIP,
tumours were investigated for ED-B expression. Immunohisto-
chemistry with the L19-SIP antibody confirmed that ED-B
expression was associated with the majority of blood vessels as
demonstrated in the SW1222 tumour model (Figure 1A). This was
observed throughout the whole of the tumour.
Distribution of fluorescence labelled L19-SIP
Triple immunofluorescence staining of vessels (CD31), L19-SIP
and perfusion (Hoechst 33342) over whole tumour sections,
demonstrated that the antibody was associated with blood vessels
in both peripheral and central regions of the tumour in the LS174T
xenograft model (Figure 1B–D). However, co-registration of
fluorescence staining for blood vessels, L19-SIP and cell nuclei
(DAPI), revealed that not all CD31-stained vessels were L19-
positive (Figure 1E), indicating that ED-B was not associated with
all tumour vessels. Furthermore, co-registration of fluorescence
staining for CD31, L19-SIP and perfusion revealed that the L19-SIP
had localised to the abluminal surface of the vessels, confirming
that expression of EDB was in the extracellular matrix (i.e., stroma)
of the tumour (Figure 1F).
Radiolabelled L19-SIP
As mentioned in the Materials and Methods section, L19-SIP
antibody was labelled following the IODO-GEN method with both
125I and
131I. Preliminary studies showed that the protein could be
labelled using the methods described above and a plateau of
labelling was found at 4min. Antigen binding of the labelled
protein was found to be 91.7% for
125I-L19-SIP and 83.7% for
131I-
L19-SIP. In addition, stability of the
125I-L19-SIP was assessed by
TLC, and was found to be 99.2% after 5 days post-labelling.
Biodistribution of
125I- and
131I-labelled L19-SIP
To compare localisation of the L19-SIP antibody in the two
colorectal xenograft models, biodistribution studies were carried
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sout using
125I-labelled antibody (Figures 2 and 3). In SW1222
tumours, the %IDg
 1 reached a maximum of 7.9 (71.3) at 6h
after injection. In comparison, this reached a maximum of 6.6
(74) at 3h in the LS174T tumours. At 24h post-injection, the
%IDg
 1 was 4.5 (71.2) and 5 (70.6) for SW1222 and LS174T,
respectively.
Blood stability studies showed that at 1h 86.4571.39% of
activity was associated with active protein (binding to antigen),
reducing to 62.0174.9% after 24h, in LS174T-bearing mice
(Figure 4). This was confirmed after the bloods from the different
time points had been run (Figure 4).
Tumour to blood ratios for the two tumour models are shown in
Table 1. Initial blood clearance was faster in the SW1222 line than
in the LS174T, but by 6h post-injection, the blood clearance for
both tumour models was comparable, with tumour to blood ratios
of approximately 1.28. However, at 24h, there was a higher tumour
to blood ratio for the SW1222, which reached 4.22 in comparison
to 3.37 for the LS174T. This led to a higher area under curve for the
SW1222, measuring 151.6%IDg
 1h
 1 vs 122.6 for the LS174T
tumours.
On the basis of these results, the SW1222 colorectal model was
selected for a RIT study. A biodistribution study with the
131I-
labelled L19-SIP was, therefore, carried out at 3, 24 and 72h post-
injection, to confirm the tumour specificity seen with
125I-labelled
L19-SIP and to investigate long-term retention of antibody for RIT.
Antibody distribution in tumour, blood and normal tissues is
A
BCD
E F
Figure 1 Immunohistochemical and immunofluorescence staining with L19-SIP antibody in SW1222 and LS174T xenograft-bearing mice. (A)
Immunohistochemical staining of SW1222 xenograft lines with L19-SIP antibody. (B–D) Multiple digital fluorescence images of an LS174T tumour injected
with Cy3-labelled L19-SIP antibody for 6h demonstrating (B) perfusion, (C) blood vessel staining and (D) L19-SIP in the same tumour section. (E) Triple
fluorescence staining of CD31 (green), L19-SIP (red) and DAPI (blue) in LS174T tumours. (F) High-power image of CD31 (green), L19-SIP (red) and
Hoechst (blue) staining in LS174T (arrow indicating abluminal localisation of the L19-SIP antibody). All images are at  20 magnification except (F) which is
at  40 magnification.
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sshown in Figure 5. Uptake values in the tumour at 3 and 24h were
5.4 (73.6) and 8 (75)%IDg
 1, respectively. By 72h, 1.7
(70.8)%IDg
 1 was still retained in the tumour.
In addition, there was an increase in tumour to blood ratio of
antibody over time, rising from 0.58 at 3h to a maximum of 28 at
24h. Although this ratio decreased by 72h, it remained relatively
high at 9.3 (Table 2).
Radioimmunotherapy
Radioimmunotherapy with
131I-L19-SIP produced a significant
effect on tumour growth and survival in SW1222 xenograft-bearing
mice. Treatment with a single dose of 55.5MBqmouse
 1 inhibited
subsequent tumour growth for a mean of approximately 14 days
(Figure 6) in comparison to control untreated mice, which showed
a steady increase in tumour growth throughout the experiment.
With the exception of one mouse, all tumours in the therapy group
subsequently re-grew, although at a slower rate to that of controls.
In addition to arrested tumour growth, RIT also resulted in a
prolongation of survival (Figure 7). While all mice in the control
group had been culled by day 32, this was extended to 68 days for
three of the treated mice. However, one out of four treated mice is
apparently cured at 193 days post-injection.
Toxicity was assessed by regular weighing, and individual
mouse weights are shown in Figure 8. In the treated group, mean
body weight reached a nadir of 4% of the starting weight at day 4
post-therapy. Initial weight was regained at day 7, and subse-
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Figure 2 Biodistribution of intravenously injected
125I-L19-SIP in SW1222 xenograft-bearing mice at 1, 3, 6 and 24h after injection. The mean7s.d. of
four different mice are shown.
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Figure 3 Biodistribution of intravenously injected
125I-L19-SIP in LS174T xenograft-bearing mice at 1, 3, 6 and 24h after injection. The mean7s.d. of four
different mice are shown.
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Figure 4 Blood stability data. Antigen binding of
125I-L19-SIP in blood of
LS174T tumour-bearing mice at 1, 3, 6 and 24h post-injection. The
mean7s.d. of four different mice are shown. Binding of the labelled protein
before injection was 84.11%.
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squently rose throughout the experiment. In comparison, control
mice showed a mean weight loss of 1% at day 4 with a recovery
exceeding initial values by day 7.
DISCUSSION
In the present study, the distribution of the L19-SIP antibody in
both SW1222 and LS174T colorectal tumour models has been
investigated using both radio- and fluorescence-labelled antibo-
dies. Furthermore, we have examined the potential of RIT against
tumour vasculature in colorectal cancer, using
131I in the SW1222
tumour model.
Using immunohistochemistry, the presence of ED-B was
demonstrated around the vasculature in both tumour models
(Figure 1A). This is supported by other studies in different tumour
types (Zardi et al, 1987; Carnemolla et al, 1989; Castellani et al,
1994; Kaczmarek et al, 1994; Neri et al, 1997; D’Ovidio et al, 1998;
Kosmehl et al, 1999; Tarli et al, 1999; Viti et al, 1999; Ebbinghaus
et al, 2004).
We subsequently demonstrated, by multi-fluorescence micro-
scopy, that fluorescence-labelled L19-SIP, when injected intra-
venously, localised specifically to tumour vessels at 6h post-
injection (Figure 1B–E). This distribution pattern was still
retained at 24h post-injection (data not shown). Fabbrini et al
(2006) also demonstrated perivascular localisation of the L19-SIP
in F9 teratocarcinoma-bearing mice. However, using high magni-
fication, we could clearly show for the first time that the antibody
is retained on the abluminal surface of the tumour blood vessels
(Figure 1F).
We also found that not all vessels stained positive for L19-SIP
(Figure 1E), suggesting that ED-B expression may only be related
to the neovasculature (i.e., immature newly formed vessels) of our
two colorectal tumour models. To clarify this, we are currently
using fluorescence microscopy and quantitative analysis to
investigate whether a correlation pattern exists between EDB
expression/L19-SIP localisation and blood vessel maturation in
both SW1222 and LS174T tumour models. Specifically, we are
looking at different vessel maturation markers, including those of
the pericyte/mural cells as well as basement membrane markers, in
different sized tumours. Preliminary data show that the majority of
blood vessels within a tumour stain for both CD31 and L19-SIP
regardless of tumour size, in comparison to control non-tumoural
tissue which shows no L19-SIP staining around the blood vessels.
These finding will be crucial when designing combined therapies
with the L19-SIP antibody.
Having confirmed ED-B expression in the two colorectal
xenografts, biodistribution experiments were performed.
125I-
labelled L19-SIP antibody demonstrated good tumour uptake
and localisation as early as 1h post-injection in both models
(Figures 2 and 3). However, we observed higher localisation of the
L19-SIP antibody in the SW1222 tumours, which reached a
maximum of 7.9%IDg
 1 at 6h. In comparison, the LS174T
tumours reached maximum of 6.6%IDg
 1 at 3h after injection.
This difference in the L19-SIP antibody distribution may reflect the
state of vascularisation within these tumours: the well-differen-
tiated SW1222 tumours are highly vascularised in comparison to
the less-differentiated LS174T tumours, which are poorly vascu-
larised and therefore less accessible to the protein.
Blood clearance of
125I-L19-SIP antibody in both tumour models
was comparable, with tumour to blood ratios of approximately
1.28 for both tumours at 6h (Table 1). Borsi et al (2002), also
demonstrated maximum localisation of the
125I-L19-SIP,
6.1%IDg
 1, at 6h in the SK-MEL-28 melanoma tumour-bearing
mice, with tumour to blood ratios of 1.22 at this time point. More
recently, using FaDu head and neck cancer xenograft-bearing
mice, Tijink et al (2006), have also demonstrated maximum
tumour localisation of
125I-L19-SIP antibody at 6h post-injection.
When targeting antibodies to solid tumours, factors such as
impaired microcirculation in newly formed vessels should be
considered, as this may prevent antibody from rapidly reaching its
target. Furthermore, the process of crossing the endothelial layer,
which precedes the L19 antibody binding to the ED-B antigen on
the abluminal surface of the vessel, could be retarded because of
interstitial pressure. In addition, the endothelium itself has long
been recognised as a natural barrier that may limit the uptake of
antibodies in solid tumours. However, in the current study, we did
not encounter these problems in our tumour models as both the
125I-L19-SIP and Cy3-labelled L19-SIP antibodies (data not shown)
had clearly localised to their targets by 1h after injection.
Interestingly, we have observed blood vessel fenestrations in the
SW1222 subcutaneous tumours using transmission electron
microscopy (data not shown), which may play a role in the
extravasation of the L19-SIP antibody and binding to its target,
although the involvement of transcytosis cannot be ruled out.
These findings, therefore, indicate few barriers to efficient
localisation of the L19-SIP antibody in our tumour model; an
Table 1 Tumour to tissue ratios of
125I-L19-SIP distribution in SW1222 and LS174T xenografts-bearing mice
1h 3h 6h 24h
Tumour to tissue ratio SW1222 LS174T SW1222 LS174T SW1222 LS174T SW1222 LS174T
Blood 0.35 0.18 0.83 0.72 1.28 1.28 4.22 3.37
Liver 1.24 0.73 3.31 2.92 4.67 1.78 15.20 8.38
Spleen 1.06 0.46 2.02 2.17 2.86 2.57 7.42 6.12
Kidney 0.38 0.28 1.14 1.15 1.73 1.28 5.03 3.57
Lung 0.85 0.44 1.60 1.37 1.62 1.25 3.53 2.88
Brain 10.93 6.42 31.09 25.32 35.80 29.73 103.72 69.36
Muscle 5.76 4.59 8.45 6.54 8.34 5.84 14.30 12.20
Stomach 1.67 1.47 2.37 1.24 1.14 1.764 2.20 1.60
Table 2 Ratios of
131I-L19-SIP distribution in SW1222 xenograft-bearing
mice
Ratio 3h 24h 72h
Blood 0.58 28.11 9.36
Liver 2.01 24.10 33.21
Spleen 0.93 13.47 12.72
Kidney 1.14 7.82 7.62
Lung 1.07 6.95 7.62
Brain 9.71 69.99 135.68
Muscle 3.44 29.39 18.08
Stomach 2.15 4.56 3.60
Colon 4.61 4.62 3.44
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combined therapy regimes.
In the current study, biodistribution experiments demonstrated
higher recorded values for tumour localisation of the
125I-L19-SIP
antibody in the SW1222 xenografts in comparison to LS174T
tumours (Figures 2 and 3). Good accessibility and prolonged
retention of the Cy3-L19-SIP antibody to its vessel-related target,
which was observed as late as 24h post-injection, was also shown
in this tumour model. In view of this prolonged retention, and as
131I has a range of emission of approximately 0.8mm and the
thickness of the tumour cord surrounding each tumour vessel in
the SW1222 tumours is around 0.5mm, this isotope was
considered the most suitable for RIT using this antibody.
Therefore the therapeutic effect of the
131I-L19-SIP antibody was
subsequently investigated in this model.
Biodistribution experiments, performed to confirm localisation
of the therapeutic
131I-L19-SIP, showed maximum tumour
localisation (8%IDg
 1) at 24h post-injection (Figure 5) in
comparison to 6h for
125I-L19-SIP (Figure 2). Interestingly, Tijink
et al (2006) also demonstrated maximum localisation of
131I-L19-
SIP (8.6%IDg
 1) in FaDu head and neck tumours at 24h.
Although higher radiolabelled antibody levels were found in blood
at 3h in the SW1222 tumour model, this fell dramatically by 24 and
72h post-injection, indicating good blood clearance and produced
high tumour to normal tissue ratios. Indeed, at 24h, tumour to
blood ratio was 28:1 (Table 2). This ratio was reduced at 72h, but
still remained high at 9.4. In another study comparing the
biodistribution of
125I-L19-SIP and
111In-L19-SIP in mice bearing
the F9 teratocarcinoma tumours, Berndorff et al (2005) found that
although tumour uptake was equal with both radionuclides,
tumour to non-tumour ratios were higher for the
125I-labelled
antibody.
RIT with
131I-L19-SIP caused significant tumour growth delay
and improved survival in the SW1222 xenograft-bearing mice. A
single dose of 55.5MBq of radiolabelled antibody significantly
inhibited tumour growth for approximately 14 days (Figure 6).
After this time, the majority of the tumours recommenced
growth; although one tumour currently appears cured (193 days
post-treatment). However, as the group size of the treated mice
was small, this finding must be considered as preliminary and
would need to be further confirmed in a larger group of mice.
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Figure 5 Biodistribution of intravenously injected
131I-L19-SIP in SW1222 xenograft-bearing mice at 3, 24 and 72h after injection. The mean7s.d. of four
different mice are shown.
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Figure 7 Survival of SW1222 xenograft-bearing nude mice after a single
injection of 55.5MBq of
131I-L19-SIP.
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SW1222 tumours compose approximately 8% of total tumour mass
(El-Emir et al, 2005). It is therefore encouraging that, although we
are only targeting this relatively small percentage of the total
tumour, the amount of localised radiolabelled antibody found by
ourselves and other authors is sufficient to produce a significant
therapeutic effect. Therefore, it can be considered very promising
for clinical trials, and future work will involve demonstrating
microscopically whether damage to both endothelium and tumour
cells occurs following RIT with
131I-L19-SIP.
No significant weight loss was observed in the treated mice
indicating that the relatively high doses of radiation used were not
toxic. Interestingly, the rapid blood clearance leading to high
tumour to blood ratios obtained at the later time points (24 and
72h) with
131I-L19-SIP may have contributed to the absence of
toxicity. It is important to note that, in this study, significant
results were obtained with doses lower than that used in other RIT
studies with the L19-SIP antibody. Berndorff et al (2005) reported
that a single injection of 74MBq
131I-L19-SIP to F9 tumour-bearing
mice resulted in a 10-day tumour growth delay and a median
survival of 22 days; 13 days longer than that of control mice. More
recently, Tijink et al (2006) also demonstrated that a single dose of
74MBq
131I-L19-SIP caused a maximum reduction in FaDu
tumour size at day 18. However, at day 26, these tumours had
re-grown to their initial size. The results reported in the current
study, therefore, compare very favourably with these high-dose
therapies, while using 25% less radioactivity (55.5 vs 74MBq), and
may be related to the high vascularity of the SW1222 tumours.
In contrast to RIT using antibodies against tumour cell-
associated antigens which are expressed only in certain cancers,
such as carcinoembryonic antigen in colorectal tumours (Pedley
et al, 2001; Mayer et al, 2003), RIT with L19-SIP antibody, which
selectively targets tumour vessels, has the advantage of being
effective in a wide range of solid tumours (Berndorff et al, 2005;
Spaeth et al, 2006; Tijink et al, 2006). Several options can now be
explored to optimise the efficacy of RIT with
131I-L19-SIP, for
example, repeated injection of the antibody. However, as the L19-
SIP is targeting the tumour vessels, which compose only a small
percentage of the tumour mass, it is unlikely that the therapy will
be totally effective as a single agent. Future experiments will,
therefore, concentrate on selecting the optimal combined com-
plementary therapies to overcome the problems of tumour
heterogeneity and treat the entire tumour. These combined
therapies are most effective when targeting different regions of
the tumour. For example, it could be combined with other forms of
RIT that target the tumour cells rather than the vasculature (Pedley
et al, 2001). Tijink et al (2006) have shown that the combination of
131I-L19-SIP with Cetuximab, an anti-EGFR antibody, enhanced
the efficacy of the RIT without causing an increase in toxicity.
In conclusion, this study demonstrates for the first time that
125I-L19-SIP and Cy3-L19-SIP showed good tumour selectivity in
two human colorectal xenografts with highly different morpho-
logies, and that RIT with
131I-L19-SIP caused a significant tumour
growth delay and improved survival. This in turn, provides the
basis for future combined therapies with RIT.
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